Swissray adds to ddR product family
Digital x-ray developer Swissray International expanded its product line with the 1999 RSNA introduction of ddRChest-System and ddRCombi, a digital x-ray unit aimed at emergency room/trauma centers. Both systems employ Swissray’s ddR-Bucky CCD-based
Digital x-ray developer Swissray International expanded its product line with the 1999 RSNA introduction of ddRChest-System and ddRCombi, a digital x-ray unit aimed at emergency room/trauma centers. Both systems employ Swissrays ddR-Bucky CCD-based digital detector.
ddRChest-System can employ a 30kW or 50kW x-ray generator and can be ready for exposure every five seconds, according to the New York City-based firm. The unit also utilizes the vendors SwissVision workstation.
ddRCombi is available in three different configurations. ddRCombi Automatic features a motorized vertical and horizontal ceiling suspension system, while ddRCombi Manual offers a manual ceiling suspension system. ddRCombi Solo allows users to bring digital technology to an existing tube stand system, according to Swissray. All three configurations employ an 80kW generator and Swissrays ddR patient table.
Both ddRCombi and ddRChest-System have received the necessary Food and Drug Administration clearances, according to Swissray. ddRChest-System will begin shipping in the second quarter of 2000 and will have a price range of $360,000 to $375,000. ddRCombi will ship in either the second or third quarter and will have a price range of $350,000 to $650,000.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
